Stock of company backed by Mukul Agrawal drops following SEBI’s insider trading violation notice

ue from exports. Neuland Laboratories Ltd has a significant global presence and capabilities, with 72 active US DMFs, 1174 KL manufacturing capacity, and 1,794 employees.

The company’s revenue is primarily generated from Europe and North America, accounting for 86% of its total revenue. Neuland Laboratories Ltd operates from Hyderabad with three manufacturing units and serves over 80 countries across APAC, MENA, LATAM, and India.

Specializing in manufacturing and selling bulk drugs, the company is a major player in the active pharmaceutical ingredients (APIs) industry. It provides end-to-end solutions for the pharmaceutical industry’s chemistry requirements, catering to both domestic and international markets.

Despite the recent setback of the insider trading violation issue and the warning letter from SEBI, Neuland Laboratories Ltd clarified that there would be no significant impact on its financials, operations, or overall activities. The shares of the company experienced a negative movement in today’s trading session, affecting its market capitalization.

Looking at the financial performance of Neuland Laboratories Ltd, its revenue in Q4FY25 decreased by 15% from the previous quarter, going from Rs 385 crore to Rs 328 crore. Similarly, the net profit also saw a substantial decrease of 59%, dropping from Rs 68 crore to Rs 28 crore during the same period.

As of March 2025, Mukul Mahavir, a key investor with 40 years of experience, holds a significant stake in the company, owning 4,00,000 equity shares, equivalent to 3.12%. Neuland Laboratories Ltd has a robust track record with over 980 DMFs filed globally, offering a wide range of 100+ APIs across various therapeutic areas.

With its strong global presence and manufacturing capabilities, Neuland Laboratories Ltd continues to maintain a solid foothold in the pharmaceutical industry, constantly striving to provide high-quality products and innovative solutions. Its commitment to excellence and adherence to regulatory standards underscore its position as a trusted leader in the pharmaceutical sector.

Despite the recent challenges, Neuland Laboratories Ltd remains focused on its core values of integrity, transparency, and customer satisfaction, ensuring that it continues to deliver value to its stakeholders and customers alike.